ATE234920T1 - Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen - Google Patents

Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen

Info

Publication number
ATE234920T1
ATE234920T1 AT93924777T AT93924777T ATE234920T1 AT E234920 T1 ATE234920 T1 AT E234920T1 AT 93924777 T AT93924777 T AT 93924777T AT 93924777 T AT93924777 T AT 93924777T AT E234920 T1 ATE234920 T1 AT E234920T1
Authority
AT
Austria
Prior art keywords
kinases
serine
kinase domain
threonine kinase
proteins
Prior art date
Application number
AT93924777T
Other languages
English (en)
Inventor
Kohei Miyazono
Peter Ten Dijke
Petra Franzen
Hidetoshi Yamashita
Carl-Henrik Heldin
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224057A external-priority patent/GB9224057D0/en
Priority claimed from GB939304680A external-priority patent/GB9304680D0/en
Priority claimed from GB939304677A external-priority patent/GB9304677D0/en
Priority claimed from GB939311047A external-priority patent/GB9311047D0/en
Priority claimed from GB939313763A external-priority patent/GB9313763D0/en
Priority claimed from GB939316099A external-priority patent/GB9316099D0/en
Priority claimed from GB939321344A external-priority patent/GB9321344D0/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE234920T1 publication Critical patent/ATE234920T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93924777T 1992-11-17 1993-11-17 Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen ATE234920T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB929224057A GB9224057D0 (en) 1992-11-17 1992-11-17 Novel protein kinase receptors
GB939304680A GB9304680D0 (en) 1993-03-08 1993-03-08 Protein kinases
GB939304677A GB9304677D0 (en) 1993-03-08 1993-03-08 Protein kinases
GB939311047A GB9311047D0 (en) 1993-05-28 1993-05-28 Protein kinases
GB939313763A GB9313763D0 (en) 1993-07-02 1993-07-02 Protein kinases
GB939316099A GB9316099D0 (en) 1993-08-03 1993-08-03 Protein kinases
GB939321344A GB9321344D0 (en) 1993-10-15 1993-10-15 Protein kinases
PCT/GB1993/002367 WO1994011502A2 (en) 1992-11-17 1993-11-17 Activin receptor-like kinases, proteins having serine threonine kinase domains and their use

Publications (1)

Publication Number Publication Date
ATE234920T1 true ATE234920T1 (de) 2003-04-15

Family

ID=27562887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93924777T ATE234920T1 (de) 1992-11-17 1993-11-17 Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen

Country Status (10)

Country Link
US (5) US6316217B1 (de)
EP (1) EP0677104B1 (de)
JP (1) JP3362151B2 (de)
KR (1) KR950704485A (de)
AT (1) ATE234920T1 (de)
AU (1) AU683431B2 (de)
CA (1) CA2149441C (de)
DE (1) DE69332779T2 (de)
NZ (1) NZ257631A (de)
WO (1) WO1994011502A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
ATE378407T1 (de) 1994-04-29 2007-11-15 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
AU709991B2 (en) * 1995-08-14 1999-09-09 Creative Biomolecules, Inc. Binding of osteogenic protein-1 (OP-1) and analogs thereof to the cell surface receptor ALK-1 and analogs thereof
AU6421498A (en) * 1997-04-28 1998-11-24 Helix Research Institute Serine/threonine protein kinase
EP2078752A3 (de) * 1998-03-13 2009-09-23 Ludwig Institute For Cancer Research ALK-1 reagiert auf TGF-beta und gibt die Signale weiter mittels SMAD-1 und SMAD-5
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
AU2002310009A1 (en) * 2001-05-21 2002-12-03 University Of Iowa Research Foundation Bmpr1a involvement in juvenile polyposis
WO2002099037A2 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP2135952A3 (de) 2003-09-15 2010-09-29 Research Development Foundation Cripto-Antagonismus von Activin und TGF-Beta-Signalisierung
WO2005077403A1 (en) * 2004-02-04 2005-08-25 Stryker Corporation Therapeutic methods using smads
CA2897218A1 (en) 2004-06-17 2006-01-26 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
KR101536506B1 (ko) 2005-09-07 2015-07-14 암젠 프레몬트 인코포레이티드 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
CN111518218A (zh) 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20190128254A (ko) 2008-05-02 2019-11-15 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
EP3058986B1 (de) 2009-03-30 2018-05-09 Acceleron Pharma Inc. Bmp-alk3-antagonisten und ihre verwendung zur förderung des knochenwachstums
US9688722B2 (en) 2012-05-04 2017-06-27 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of prolyl oligopeptidase and methods of use
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN105738630A (zh) * 2016-02-16 2016-07-06 林兴 丝/苏氨酸激酶抑制蛋白在治疗免疫性肝纤维化药物中的应用
CN105617369A (zh) * 2016-02-17 2016-06-01 林兴 丝/苏氨酸激酶抑制蛋白在治疗化学性肝纤维化药物中的应用
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
JP7030776B2 (ja) 2016-07-20 2022-03-07 ノバルティス アーゲー アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
WO2018067879A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
PE20201282A1 (es) 2017-11-24 2020-11-24 Novartis Ag Derivados de piridinona y su uso como inhibidores selectivos de alk-2
WO2020086580A1 (en) 2018-10-22 2020-04-30 Carlson William D Therapeutic combinations of tdfrps and additional agents and methods of use
EP4142769A4 (de) 2020-04-28 2024-05-15 Acceleron Pharma Inc. Actrii-proteine und verwendung bei der behandlung von postkapillarer pulmonaler hypertonie
WO2022046840A1 (en) * 2020-08-26 2022-03-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Hybrid allosteric receptor-engineered stem cells
WO2023019185A1 (en) * 2021-08-10 2023-02-16 Gentibio, Inc. Compositions and methods for engineering stable tregs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154434B1 (de) * 1984-02-17 1993-01-27 Genentech, Inc. Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren
AU3920693A (en) * 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
AU683073B2 (en) * 1993-06-07 1997-10-30 Amgen, Inc. Hybrid receptor molecules
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
ATE378407T1 (de) * 1994-04-29 2007-11-15 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor

Also Published As

Publication number Publication date
NZ257631A (en) 1996-03-26
US6271365B1 (en) 2001-08-07
WO1994011502A3 (en) 1994-07-07
JP3362151B2 (ja) 2003-01-07
US6207814B1 (en) 2001-03-27
DE69332779D1 (de) 2003-04-24
US6982319B2 (en) 2006-01-03
JPH08505049A (ja) 1996-06-04
US6316217B1 (en) 2001-11-13
CA2149441C (en) 2004-03-02
CA2149441A1 (en) 1994-05-26
AU5432094A (en) 1994-06-08
EP0677104A1 (de) 1995-10-18
US20020123139A1 (en) 2002-09-05
AU683431B2 (en) 1997-11-13
US6331621B1 (en) 2001-12-18
WO1994011502A2 (en) 1994-05-26
KR950704485A (ko) 1995-11-20
DE69332779T2 (de) 2003-10-23
EP0677104B1 (de) 2003-03-19

Similar Documents

Publication Publication Date Title
DE69332779D1 (de) Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
BR0015110A (pt) Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
AR007856A1 (es) Compuestos heterociclicos fusionados como inhibidores de proteina tirosina, quinasa, sus metodos de prepraracion, intermediarios, uso en medicina ycomposiciones farmaceuticas que los contienen
DK0674641T3 (da) Pyrrolopyrimidiner som CRF-antagonister
ES2173864T3 (es) Compuestos heteroarilicos sustituidos con estirilo que inhiben tirosina quinasa del receptor de egf.
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
BRPI0413018B8 (pt) composto, e, uso de um composto
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
CO5190686A1 (es) Compuesto de indazol y composiciones farmaceuticas para la inhibicion de proteina kinasa
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
PT711292E (pt) Compostos espiro aza actuando no sistema colinergico com actividade agonista muscarinica
ES2124668B1 (es) "nuevosl-arilpirazoles con propiedades plaguicidas.
MD1616G2 (ro) Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
AU1557400A (en) Absorbent elements for hygiene articles
CO4890836A1 (es) Capa para adquisicion de liquidos para articulos absorbentes
SE9700606L (sv) Vätskegenomsläppligt höljesskikt till absorberande alster
BR0111869A (pt) Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
ATE242234T1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE59601878D1 (de) Verwendung von schwerflüchtigen pyrazolderivaten mit hydrophilen gruppen als nitrifikationsinhibitoren
EP0402889A3 (de) Polymere Polyalkyl-1-oxa-diazaspirodecane
BR9607335A (pt) Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
DK0563256T3 (da) Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties